Resistance Training and Clinical Status in Patients With Post Discharge Symptoms After Covid-19
CompletedNot applicableNCT04797871
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
COVID-19 survivors commonly exhibit a marked extra-respiratory complication affecting the cardiac (arrhythmias and myocardial injury), renal (acute kidney injury), gastrointestinal, nervous (neuropathy, encephalopathy), endocrine and musculoskeletal (weakness, pain, and fatigue) systems. In this context, several studies have found that resistance training intervention promotes important health-related benefits, including cardiac function, compared to aerobic exercise training. Other exercise adaptations include increased skeletal muscle metabolism function, yet physio/psychological adaptations are known to be limited in COVID-19 survivors. Hence, given that resistance training intervention is implemented in a manner that is tolerable to the individual patient, it may be a potential beneficiary "personalized" rehabilitation treatment for patients with COVID-19 syndrome ambulatory. The "EXER-COVID Clinical Study" project aims at determining the role of personalized exercise intervention in the treatment of post-COVID-19 syndrome ambulatory patients.
Study details
- Official title
- Resistance Training Intervention on the Clinical Status in Patients With Post Discharge Symptoms After Covid-19: The "EXER-COVID Study"
- Conditions
- Covid19
- SARS-CoV2
- Fatigue Syndrome, Chronic
- Stress, Psychological
- Pain, Chronic
- Interventions
- Behavioral: Resistance training
- Behavioral: Standard care
- Sponsor
- Universidad Pública de Navarra
- Collaborators
- Fundacion Miguel Servet; Complejo Hospitalario de Navarra
- Start date
- 2021-03-08
- Primary completion
- 2022-09-18
- Sex
- All
- Age range
- from 18 Years to 60 Years
- Results posted
- No results posted in this snapshot
- Countries
- Spain
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age ≥ 18 years * SARS-CoV-2 diagnosed using real-time reverse transcriptase polymerase chain reaction (PCR) tests or positive for SARS-CoV-2 virus antigen \>90 days before randomization. * Still present a chronic symptomatic phase lasting \>90 days since debut of symptoms. * Have not been hospitalized. * There is no evidence on clinical records of pneumonia or any other organ failure related to SARS-CoV-2. * Capable and willing to provide an informed consent. Exclusion Criteria: * Pregnancy or breast-feeding. * Present atrial fibrillation. * Diagnosed with acute myocarditis. * Health conditions that prevent participating in the exercise intervention * Patients who cannot undergo VO2max (e.g. acute heart attack or unstable angina, aortic stenosis, acute endocarditis / pericarditis, uncontrolled high blood pressure, acute thromboembolism, severe heart failure, respiratory failure and uncontrolled acute decompensated diabetes mellitus or low blood sugar). * Treatment with IL-6 receptor antagonists (tocilizumab, kevzara) within the last month due to drug interference with the cardiopulmonary exercise adaptations.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04797871